Updated survival and safety results from the phase 2 study (ANNIE) of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (1139) von Liu, Guochen, Xian, Bingna, Li, Jing, Feng, Yanling, Huang, He, Wan, Ting, Huang, Qidan, Liu, Jihong

Volltext

A novel combo of niraparib and anlotinib in platinum-resistant ovarian cancer, the final efficacy and safety report of ANNIE study, a phase II, multi-center trial (LBA 2) von Liu, Guochen, Feng, Yanling, Li, Jing, Huang, He, Wan, Ting, Huang, Qidan, Xian, Bingna, Lin, An, Kong, Beihua, Liu, Ji hong

Volltext

Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer von Liu, Guochen, Liu, Jihong, Xian, Bingna, Li, Jing, Feng, Yanling, Huang, He, Wan, Ting, Huang, Qidan, Tu, Hua, Gu, Haifeng, Liu, Zhimin

Volltext

Food production seasoning device von BING XIAN, XU BINGNA

Volltext bestellen